186 related articles for article (PubMed ID: 22586182)
21. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.
Klyuchnikov E; Bacher U; Kröger NM; Hari PN; Ahn KW; Carreras J; Bachanova V; Bashey A; Cohen JB; D'Souza A; Freytes CO; Gale RP; Ganguly S; Hertzberg MS; Holmberg LA; Kharfan-Dabaja MA; Klein A; Ku GH; Laport GG; Lazarus HM; Miller AM; Mussetti A; Olsson RF; Slavin S; Usmani SZ; Vij R; Wood WA; Maloney DG; Sureda AM; Smith SM; Hamadani M
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2091-2099. PubMed ID: 26253007
[TBL] [Abstract][Full Text] [Related]
22. ⁹⁰Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma.
Gopal AK; Guthrie KA; Rajendran J; Pagel JM; Oliveira G; Maloney DG; Matesan MC; Storb RF; Press OW
Blood; 2011 Jul; 118(4):1132-9. PubMed ID: 21508413
[TBL] [Abstract][Full Text] [Related]
23. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials.
Piñana JL; Martino R; Gayoso J; Sureda A; de la Serna J; Díez-Martín JL; Vazquez L; Arranz R; Tomás JF; Sampol A; Solano C; Delgado J; Sierra J; Caballero D;
Haematologica; 2010 Jul; 95(7):1176-82. PubMed ID: 20107156
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
Sureda A; Zhang MJ; Dreger P; Carreras J; Fenske T; Finel H; Schouten H; Montoto S; Robinson S; Smith SM; Boumedil A; Hamadani M; Pasquini MC
Cancer; 2018 Apr; 124(8):1733-1742. PubMed ID: 29424927
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic stem cell transplantation in follicular lymphoma.
Khouri IF
Best Pract Res Clin Haematol; 2011 Jun; 24(2):271-7. PubMed ID: 21658623
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study.
Ibatici A; Pica GM; Nati S; Vitolo U; Botto B; Ciochetto C; Petrini M; Galimberti S; Ciabatti E; Orciuolo E; Zinzani PL; Cascavilla N; Guolo F; Fraternali Orcioni G; Carella AM
Br J Haematol; 2014 Mar; 164(5):710-6. PubMed ID: 24344981
[TBL] [Abstract][Full Text] [Related]
27. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
[TBL] [Abstract][Full Text] [Related]
28. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma.
Nademanee A; Forman S; Molina A; Fung H; Smith D; Dagis A; Kwok C; Yamauchi D; Anderson AL; Falk P; Krishnan A; Kirschbaum M; Kogut N; Nakamura R; O'donnell M; Parker P; Popplewell L; Pullarkat V; Rodriguez R; Sahebi F; Smith E; Snyder D; Stein A; Spielberger R; Zain J; White C; Raubitschek A
Blood; 2005 Oct; 106(8):2896-902. PubMed ID: 16002426
[TBL] [Abstract][Full Text] [Related]
29. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
Witzig TE; Flinn IW; Gordon LI; Emmanouilides C; Czuczman MS; Saleh MN; Cripe L; Wiseman G; Olejnik T; Multani PS; White CA
J Clin Oncol; 2002 Aug; 20(15):3262-9. PubMed ID: 12149300
[TBL] [Abstract][Full Text] [Related]
30. Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90 ibritumomab tiuxetan.
Molina A; Krishnan A; Fung H; Flinn IW; Inwards D; Winter JN; Nademanee A
Curr Stem Cell Res Ther; 2007 Sep; 2(3):239-48. PubMed ID: 18220907
[TBL] [Abstract][Full Text] [Related]
31. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients.
Leahy MF; Turner JH
Blood; 2011 Jan; 117(1):45-52. PubMed ID: 20864582
[TBL] [Abstract][Full Text] [Related]
32. Collection of hematopoietic stem cells after previous radioimmunotherapy is feasible and does not impair engraftment after autologous stem cell transplantation in follicular lymphoma.
Derenzini E; Stefoni V; Maglie R; Casadei B; Pellegrini C; Broccoli A; Stefani G; Fanti S; Motta MR; Narducci R; Argnani L; Zinzani PL
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1695-701. PubMed ID: 24055654
[TBL] [Abstract][Full Text] [Related]
33. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.
Morschhauser F; Radford J; Van Hoof A; Vitolo U; Soubeyran P; Tilly H; Huijgens PC; Kolstad A; d'Amore F; Gonzalez Diaz M; Petrini M; Sebban C; Zinzani PL; van Oers MH; van Putten W; Bischof-Delaloye A; Rohatiner A; Salles G; Kuhlmann J; Hagenbeek A
J Clin Oncol; 2008 Nov; 26(32):5156-64. PubMed ID: 18854568
[TBL] [Abstract][Full Text] [Related]
34. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
35. Current status and future perspectives for yttrium-90 ((90)Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma.
Gisselbrecht C; Bethge W; Duarte RF; Gianni AM; Glass B; Haioun C; Martinelli G; Nagler A; Pettengell R; Sureda A; Tilly H; Wilson K
Bone Marrow Transplant; 2007 Dec; 40(11):1007-17. PubMed ID: 17922042
[TBL] [Abstract][Full Text] [Related]
36. Long-term efficacy of (90)Y ibritumomab tiuxetan therapy in follicular non-Hodgkin lymphoma and health-related quality of life.
Andrade-Campos MM; Montes-Limón AE; Soro-Alcubierre G; Grasa JM; Lopez-Gómez L; Baringo T; Giraldo P
Ann Hematol; 2014 Dec; 93(12):1985-92. PubMed ID: 24985089
[TBL] [Abstract][Full Text] [Related]
37. Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Kang BW; Kim WS; Kim C; Jang G; Lee SS; Choi YH; Lee DH; Kim SW; Kim S; Ryu JS; Huh J; Lee JS; Suh C
Invest New Drugs; 2010 Aug; 28(4):516-22. PubMed ID: 19547918
[TBL] [Abstract][Full Text] [Related]
38. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.
Schilder R; Molina A; Bartlett N; Witzig T; Gordon L; Murray J; Spies S; Wang H; Wiseman G; White C
Cancer Biother Radiopharm; 2004 Aug; 19(4):478-81. PubMed ID: 15453962
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
Karmali R; Kassar M; Venugopal P; Shammo JM; Fung HC; Bayer R; O'Brien T; Gregory SA
Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):467-74. PubMed ID: 21700527
[TBL] [Abstract][Full Text] [Related]
40. Relapsed follicular lymphoma sequentially treated with rituximab and 90Y-ibritumomab tiuxetan. Case report.
Papajik T; Prochazka V; Raida L; Kubova Z; Myslivecek M; Drymlova J; Buriankova E; Kucerova L; Indrak K
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2007 Jun; 151(1):109-12. PubMed ID: 17690751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
